SEC Comment Letter 0000000000-24-010857 to Evogene Ltd. (EVGN)
Evogene Ltd.
Date: Sept. 24, 2024 · CIK: 0001574565 · Accession: 0000000000-24-010857
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282218
Letter
September 24, 2024 Ofer Haviv President and Chief Executive Officer Evogene Ltd. 13 Gad Feinstein Street, Park Rehovot Rehovot 7638517, Israel Re:Evogene Ltd. Registration Statement on Form F-1 Filed September 19, 2024 File No. 333-282218 Dear Ofer Haviv: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Conlon Danberg at 202-551-4466 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc:Mike Rimon, Esq.
Show Raw Text
September 24, 2024
Ofer Haviv
President and Chief Executive Officer
Evogene Ltd.
13 Gad Feinstein Street, Park Rehovot
Rehovot 7638517, Israel
Re:Evogene Ltd.
Registration Statement on Form F-1
Filed September 19, 2024
File No. 333-282218
Dear Ofer Haviv:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Conlon Danberg at 202-551-4466 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:Mike Rimon, Esq.